Pediatric Neurology
Volume 34, Issue 1 , Pages 1-6 , January 2006

Pharmacotherapy of Spasticity in Children With Cerebral Palsy

  • Alberto Verrotti, MD, PhD

      Affiliations

    • Department of Medicine, Section of Pediatrics, University of Chieti, Chieti, Italy
    • Corresponding Author InformationCommunications should be addressed to: Dr. Verrotti; Department of Pediatrics; University of Chieti; Ospedale Policlinico; Via dei Vestini 5; 66013 Chieti, Italy
    • ,
  • Rita Greco, MD

      Affiliations

    • Department of Medicine, Section of Pediatrics, University of Chieti, Chieti, Italy
    • ,
  • Alberto Spalice, MD

      Affiliations

    • Department of Pediatrics, University of Rome, Rome, Italy
    • ,
  • Francesco Chiarelli, MD

      Affiliations

    • Department of Medicine, Section of Pediatrics, University of Chieti, Chieti, Italy
    • ,
  • Paola Iannetti, MD

      Affiliations

    • Department of Pediatrics, University of Rome, Rome, Italy

Received 18 January 2005 ,Accepted 12 May 2005.

References 

  1. Sanger TD , Delgado MR , Gaebler-Spira D . Classification and definitions of disorders caused by hypertonia in childhood . Pediatrics . 2003;111:89–97
  2. O’Brien CF . Treatment of spasticity with botulinum toxin . Clin J Pain . 2002;18(6 Suppl.):182–190
  3. Mayer NH . Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion . Muscle Nerve . 1997;6(Suppl.):1–13
  4. Gans BM , Glenn MB . The practical management of spasticity in children and adults . In:  Glenn MB ,  Whyte J editor. Philadelphia: Lea and Febiger; 1990;p. 1–7
  5. Trimble MH , Du P , Brunt D . Modulation of triceps surae H-reflexes as a function of the reflex activation history during standing and stepping . Brain Res . 2000;858:274–283
  6. Shapiro BK . Cerebral palsy (A reconceptualization of the spectrum) . J Pediatr . 2004;145(2 Suppl.):3–7
  7. Lebiedowska MK , Gaebler-Spira D , Burns RS , Fisk JR . Biomechanic characteristics of patients with spastic and dystonic hypertonia in cerebral palsy . Arch Phys Med Rehabil . 2004;85:875–880
  8. Young RR . Spasticity (A review) . Neurology . 1994;44:12–20
  9. Crenna P . Spasticity and ‘spastic’ gait in children with cerebral palsy . Neurosci Biobehav Rev . 1998;22:571–578
  10. Johnson A . Cerebral palsies (Epidemiology and causal pathways) . Arch Dis Child . 2000;83:279
  11. Mutch L , Alberman E , Hagberg B , Kodama K , Perat MV . Cerebral palsy epidemiology (Where are we now and where are we going?) . Dev Med Child Neurol . 1992;34:547–551
  12. Sanger TD , Delgado MR , Gaebler-Spira D , Hallett M , Mink JW  Task Force on Childhood Motor Disorders . Classification and definition of disorders causing hypertonia in childhood . Pediatrics . 2003;111:89–97
  13. Brown JK . Disorders of central nervous system. Cerebral palsy . In:  Campbell AGM ,  McIntosh N editor. Forfar and Arneil’s textbook of paediatrics . 4th ed.. Edinburgh: Churchill Livingstone; 1992;p. 802–820
  14. De Felice C , Toti P , Laurini RN , et al.   Early neonatal brain damage in histologic chorioamnionitis . J Pediatr . 2001;138:101–104
  15. Hagberg H , Wennerholm UB , Savman K . Sequelae of chorioamnionitis . Curr Opin Infect Dis . 2002;15:301–306
  16. Nelson KB , Grether JK , Dambrosia JM . Neonatal cytokines and cerebral palsy in very preterm infants . Pediatr Res . 2003;53:600–607
  17. Costeff H . Estimated frequency of genetic and nongenetic causes of congenital idiopathic cerebral palsy in west Sweden . Ann Hum Genet . 2004;68:515–520
  18. Nelson KB , Dambrosia JM , Iovannisci DM , Cheng S , Grether JK , Lammer E . Genetic polymorphisms and cerebral palsy in very preterm infants . Pediatr Res . 2005;57:494–499
  19. Whyte J , Robinson KM . Pharmacologic management . In:  Glenn MB ,  Whyte J editor. The practical management of spasticity in children and adults . Philadelphia: Lea and Febiger; 1990;p. 201–226
  20. Albright AL . Spastic cerebral palsy (Approaches to drug treatment) . CNS Drugs . 1995;4:17–27
  21. Katz RT , Campagnolo DI . Pharmacologic management of spasticity . Phys Med Rehabil (State of the Art Reviews) . 1994;8:473–480
  22. Young RR , Emre M , Nance PW . Current issues in spasticity management . Neurologist . 1997;3:261–275
  23. Ruffalo RL , Thompson JF , Segal JL . Diazepam–cimetidine drug interaction (A clinically significant effect) . J South Med Assoc . 1981;74:1075–1078
  24. Koeppen D . Memory and benzodiazepines (Animal and human studies with 1,4 benzodiazepines and clonazepam (1,5 benzodiazepine)) . Drug Dev Res . 1984;4:555–566
  25. Young RR , Delwaide PJ . Drug therapy (Spasticity (second of two parts)) . N Engl J Med . 1981;304:96–99
  26. Dimitrijevic MR . Evaluation and treatment of spasticity . J Neurol Rehabil . 1995;9:97–110
  27. Terrence CF , Fromm GH , Roussan MS . Baclofen (Its effect on seizure frequency) . Arch Neurol . 1983;40:28–29
  28. Terrence CF , Fromm GH . Complications of baclofen withdrawal . Arch Neurol . 1981;38:588–589
  29. Albright AL . Neurosurgical treatment of spasticity and other pediatric movement disorders . J Child Neurol . 2003;18:67–78
  30. Gilmartin R , Bruce D , Storrs BB . Intrathecal baclofen for management of spastic cerebral palsy (Multicenter trial) . J Child Neurol . 2000;15:71–77
  31. Coffey RJ , Cahell D , Steers W . Intrathecal baclofen for intractable spasticity of spinal origin (Results of a long-term multicenter study) . J Neurosurg . 1993;78:226–232
  32. Albright AL , Cervi A , Singletary J . Intrathecal baclofen for spasticity in cerebral palsy . JAMA . 1991;265:1418–1422
  33. Azouvi P , Mane M , Thiebaut JB . Intrathecal baclofen administration for control of severe spinal spasticity (Functional improvement and long-term follow-up) . Arch Phys Med Rehabil . 1996;77:35–39
  34. Campbell SK , Almeida GL , Penn RD , Corcos DM . The effects of intrathecally administered baclofen on function in patients with spasticity . Phys Ther . 1995;75:352–362
  35. Nance P , Schryvers O , Schmidt B . Intrathecal baclofen therapy for adults with spinal spasticity (Therapeutic efficacy and effect on hospital admissions) . Can J Neurol Sci . 1995;22:22–29
  36. Campbell WM , Ferrel A , McLaughlin JF . Long-term safety and efficacy of continuous intrathecal baclofen . Dev Med Child Neurol . 2002;44:660–665
  37. Bjornson KF , Mclaughlin JF , Loeser JD , et al.   Oral motor, communication, and nutritional status of children during intrathecal baclofen therapy (A descriptive pilot study) . Arch Phys Med Rehabil . 2003;84:500–506
  38. Katz RT , Rymer WZ . Spastic hypertonia (Mechanisms and measurement) . Arch Phys Med Rehabil . 1989;70:144–155
  39. Armstrong RW , Steinbok P , Cochrane DD . Intrathecally administered baclofen for treatment of children with spasticity of cerebral origin . J Neurosurg . 1997;87:409–414
  40. Rawicki B . Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump (Long-term follow-up review of 18 patients) . J Neurosurg . 1999;91:733–736
  41. Levin AB , Sperling KB . Complications associated with infusions pumps implanted for spasticity . Stereotact Funct Neurosurg . 1995;65:147–151
  42. Murphy NA , Irwin MC , Hoff C . Intrathecal baclofen therapy in children with cerebral palsy (Efficacy and complications) . Arch Phys Med Rehabil . 2002;83:1721–1725
  43. Chan CH . Dantrolene sodium and hepatic injury . Neurology . 1990;40:1423–1427
  44. Badell A . The effect of medications that reduce spasticity in the management of spastic cerebral palsy . J Neurol Rehabil . 1991;5(1 Suppl.):13–14
  45. Katrak PH , Cole JMD , Poulos CJ . Objective assessment of spasticity, strength, and function with early exhibition of dantrolene sodium after cerebrovascular accident (A randomized double-blind study) . Arch Phys Med Rehabil . 1992;73:4–9
  46. Dall JT , Harmon RL , Quinn CM . Use of clonidine for treatment of spasticity arising from various forms of brain injury (A case series) . Brain Injury . 1996;10:453–458
  47. Donovan WH , Carter RE , Rossi CD . Clonidine effect of spasticity (A clinical trial) . Arch Phys Med Rehabil . 1988;69:193–194
  48. Nance PW . Tizanidine (An alpha2-agonist imidazoline with antispasticity effects) . Today’s Therapeutic Trends . 1997;15:11–25
  49. Gracies JM , Nance P , Elovic E . Traditional pharmacological treatments for spasticity, part II (General and regional treatments) . Muscle Nerve . 1997;6(Suppl.):92–120
  50. Nance PW , Young RR . Antispasticity medications . Phys Med Rehabil Clin North Am . 1999;10:337–355
  51. Kaplan MS . Tizanidine (Another tool in the management of spasticity) . J Head Trauma Rehabil . 1997;12:93–97
  52. Love SC , Valentine JP , Blair EM . The effect of botulinum toxin type A on the functional ability of the child with spastic hemiplegia (A randomized controlled trial) . Eur J Neurol . 2001;8(5 Suppl.):50–58
  53. Koman LA , Brashear A , Rosenfeld S , et al.   Botulinum toxin type A neuromuscular blockade in the treatment of equines foot deformity in cerebral palsy (A multicenter, open-label clinical trial) . Pediatrics . 2001;108:1062–1071
  54. Brin MF . Botulinum toxin (Chemistry, pharmacology, toxicity, and immunology) . Muscle Nerve . 1997;6(Suppl.):146–198
  55. Katz RT , Rymer WZ . Spastic hypertonia (Mechanisms and measurement) . Arch Phys Med Rehabil . 1989;70:144–155
  56. Foran PG , Mohammed N , Lisk GO . Evaluation of the therapeutic usefulness of botulinum neurotoxin B, C1, EF compared to the long-lasting type A (Basis for distinct durations of inhibition of exocytosis in central neurons) . J Biol Chem . 2002;278:1363–1371
  57. Aoki KR , Guyer B . Botulinum toxin type A and other botulinum toxin serotypes (A comparative review of biochemical and pharmacological actions) . Eur J Neurol . 2001;8(5 Suppl.):21–25
  58. Schwerin A , Berweck S , Fietzek UM , Heinen F . Botulinum toxin B treatment in children with spastic movement disorders (A pilot study) . Pediatr Neurol . 2004;31:109–113
  59. Koman LA , Paterson Smith B , Balkrishnan R . Spasticity associated with cerebral palsy in children (Guidelines for the use of botulinum A toxin) . Paediatr Drugs . 2003;5:11–23
  60. Wong V . Use of botulinum toxin injection in 17 children with spastic cerebral palsy . Pediatr Neurol . 1998;18:124–131
  61. Hamjian JA , Walker FO . Serial neurophysiological studies of intramuscular botulinum-A toxin in humans . Muscle Nerve . 1994;17:1385–1392
  62. Sloop RR , Escutin RO , Matus JA . Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A . Neurology . 1996;46:1382–1386
  63. Sloop RR , Cole BA , Escutin RO . Human response to botulinum toxin injection (Type B compared with type A) . Neurology . 1997;49:189–194
  64. Yang TF , Fu CP , Kao NT . Effect of botulinum toxin A on cerebral palsy with upper limb spasticity . Am J Phys Med Rehabil . 2003;82:284–289
  65. Russman BS , Tilton A , Gormley ME . Cerebral palsy (A rational approach to a treatment protocol, and the role of botulinum toxin in treatment) . Muscle Nerve . 1997;6(Suppl.):181–193
  66. Molenaers G , Desloovere K , Eyssen M . Botulinum toxin type A treatment of cerebral palsy (An integrated approach) . Eur Neurol . 1999;6(Suppl.):51–57
  67. Hurvitz EA , Conti GE , Brown SH . Changes in movement characteristics of the spastic upper extremity after botulinum toxin injection . Arch Phys Med Rehabil . 2003;84:444–454
  68. Boyd RN , Hays RM . Current evidence for the use of botulinum toxin type A in the management of children with cerebral palsy (A systematic review) . Eur J Neurol . 2001;8(5 Suppl.):1–20
  69. Consensus Development Conference Report . Clinical use of botulinum toxin. Reprinted from NIH Consensus Development Conference Consensus Statement . 1990;8:12–14
  70. Rosenbaum P . Controversial treatment of spasticity (Exploring alternative therapies for motor function in children with cerebral palsy) . J Child Neurol . 2003;18:89–94
  71. Dietz V . Spastic movement disorder (What is the impact of research on clinical practice?) . J Neurol Neurosurg Psychiatry . 2003;74:820–821

PII: S0887-8994(05)00252-3

doi: 10.1016/j.pediatrneurol.2005.05.001

Pediatric Neurology
Volume 34, Issue 1 , Pages 1-6 , January 2006

Article Tools

* Image Usage & Resolution